|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2008-7-15
|
|
pubmed:abstractText |
Using a comprehensive set of discovery and optimization tools, antibodies were produced with the ability to neutralize SARS coronavirus (SARS-CoV) infection in Vero E6 cells and in animal models. These anti-SARS antibodies were discovered using a novel DNA display method, which can identify new antibodies within days. Once neutralizing antibodies were identified, a comprehensive and effective means of converting the mouse sequences to human frameworks was accomplished using HuFR (human framework reassembly) technology. The best variant (61G4) from this screen showed a 3.5-4-fold improvement in neutralization of SARS-CoV infection in vitro. Finally, using a complete site-saturation mutagenesis methodology focused on the CDR (complementarity determining regions), a single point mutation (51E7) was identified that improved the 80% plaque reduction neutralization of the virus by greater than 8-fold. These discovery and evolution strategies can be applied to any emerging pathogen or toxin where a causative agent is known.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-10916143,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-12504553,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-12514726,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-12969565,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-14654628,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-14670693,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-14718652,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-15289056,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-15655773,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-15827197,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-15848073,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-15848074,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-15857975,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-16824601,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-16970022,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-17161858,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-17215466,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-17283614,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-17287272,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-3871353,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-8112468,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18480090-8604223
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1741-0126
|
|
pubmed:author |
pubmed-author:ClementsT LTL,
pubmed-author:DirmeierR PRP,
pubmed-author:FreyG JGJ,
pubmed-author:HollandT FTF,
pubmed-author:KellerMM,
pubmed-author:KimmelB EBE,
pubmed-author:LewisL MLM,
pubmed-author:LiJ QJQ,
pubmed-author:OOIS KSK,
pubmed-author:RogersJJ,
pubmed-author:SatoA KAK,
pubmed-author:SchoeppR JRJ,
pubmed-author:SchröderOO,
pubmed-author:TozerE CEC,
pubmed-author:UDAKK,
pubmed-author:WongKK,
pubmed-author:WoodnuttGG
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
495-505
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18480090-Animals,
pubmed-meshheading:18480090-Antibodies, Viral,
pubmed-meshheading:18480090-Antibody Specificity,
pubmed-meshheading:18480090-Cercopithecus aethiops,
pubmed-meshheading:18480090-Communicable Diseases, Emerging,
pubmed-meshheading:18480090-Directed Molecular Evolution,
pubmed-meshheading:18480090-Drug Discovery,
pubmed-meshheading:18480090-Humans,
pubmed-meshheading:18480090-Mice,
pubmed-meshheading:18480090-Mice, Inbred BALB C,
pubmed-meshheading:18480090-Neutralization Tests,
pubmed-meshheading:18480090-Point Mutation,
pubmed-meshheading:18480090-SARS Virus,
pubmed-meshheading:18480090-Severe Acute Respiratory Syndrome,
pubmed-meshheading:18480090-Vero Cells
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases.
|
|
pubmed:affiliation |
Verenium Corporation, 4955 Directors Place, San Diego, CA 92121, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|
